197 related articles for article (PubMed ID: 17032155)
1. Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody.
Ikegami S; Yamakami K; Ono T; Sato M; Suzuki S; Yoshimura I; Asano T; Hayakawa M; Tadakuma T
Hum Gene Ther; 2006 Oct; 17(10):997-1005. PubMed ID: 17032155
[TBL] [Abstract][Full Text] [Related]
2. Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen.
Ikegami S; Tadakuma T; Yamakami K; Ono T; Suzuki S; Yoshimura I; Asano T; Hayakawa M
Hum Cell; 2005 Mar; 18(1):17-23. PubMed ID: 16130896
[TBL] [Abstract][Full Text] [Related]
3. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
[TBL] [Abstract][Full Text] [Related]
4. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
[TBL] [Abstract][Full Text] [Related]
5. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
Moffatt S; Papasakelariou C; Wiehle S; Cristiano R
Gene Ther; 2006 May; 13(9):761-72. PubMed ID: 16453011
[TBL] [Abstract][Full Text] [Related]
6. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.
Ikegami S; Tadakuma T; Suzuki S; Yoshimura I; Asano T; Hayakawa M
Jpn J Cancer Res; 2002 Oct; 93(10):1154-63. PubMed ID: 12417046
[TBL] [Abstract][Full Text] [Related]
7. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
8. Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer.
Hattori Y; Maitani Y
Cancer Sci; 2006 Aug; 97(8):787-98. PubMed ID: 16800821
[TBL] [Abstract][Full Text] [Related]
9. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Uchida A; O'Keefe DS; Bacich DJ; Molloy PL; Heston WD
Urology; 2001 Aug; 58(2 Suppl 1):132-9. PubMed ID: 11502468
[TBL] [Abstract][Full Text] [Related]
10. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
11. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Zhen S; Takahashi Y; Narita S; Yang YC; Li X
Oncotarget; 2017 Feb; 8(6):9375-9387. PubMed ID: 28030843
[TBL] [Abstract][Full Text] [Related]
13. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
14. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells.
Suzuki S; Tadakuma T; Kunitomi M; Takayama E; Sato M; Asano T; Nakamura H; Hayakawa M
Urol Int; 2001; 67(3):216-23. PubMed ID: 11598449
[TBL] [Abstract][Full Text] [Related]
15. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
Zhao FJ; Zhang S; Yu ZM; Xia SJ; Li H
Prostate Cancer Prostatic Dis; 2009; 12(2):166-71. PubMed ID: 18626508
[TBL] [Abstract][Full Text] [Related]
16. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells.
Meng P; Dong QC; Tan GG; Wen WH; Wang H; Zhang G; Wang YZ; Jing YM; Wang C; Qin WJ; Yuan JL
BMC Urol; 2017 Feb; 17(1):14. PubMed ID: 28193277
[TBL] [Abstract][Full Text] [Related]
20. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB
Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
